1-Boc-4-甲基-4-哌啶甲酸 | 189321-63-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-Boc-4-甲基-4-哌啶甲酸
• 中文别名: 1-N-BOC-4-甲基哌啶-4-甲酸；1-叔丁氧羰基-4-甲基哌啶-4-甲酸；1-BOC-4-甲基-哌啶-4-羧酸；N-BOC-4-甲基-4-哌啶甲酸；1-boc-4-甲基-4-甲酸-哌啶
• 英文名称: 1-(tert-butoxycarbonyl)-4-methylpiperidine-4-carboxylic acid
• 英文别名: 1-tert-butoxycarbonyl-4-methyl-4-piperidinecarboxylic acid；1-Boc-4-methylpiperidine-4-carboxylic acid；1-(tert-butyloxycarbonyl)-4-methylpiperidine-4-carboxylic acid；4-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid；1-Boc-4-methyl-4-piperidinecarboxylic acid；N-t-butoxycarbonyl-4-methylpiperidine-4-carboxylic acid
• CAS: 189321-63-9
• 化学式: C₁₂H₂₁NO₄
• mdl: MFCD02179132
• 分子量: 243.303
• InChiKey: OKBNEDPOUYRYNP-UHFFFAOYSA-N

物化性质

• 沸点：
  354.3±35.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存储条件：0-10°C，需置于惰性气体中，避免与空气接触及加热。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-4-Methylpiperidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-4-Methylpiperidine-4-carboxylic acid
CAS number: 189321-63-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H21NO4
Molecular weight: 243.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-4-甲基-4-哌啶甲酸 在 4-二甲氨基吡啶 、 nickel(II) perchlorate hexahydrate 、 苯硅烷 、 4,4'-二叔丁基-2,2'-二吡啶 、 N,N'-二异丙基碳二亚胺 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 1.0h， 生成 1-Boc-4-甲基哌啶
  参考文献：
  名称：

  镍催化的 Barton 脱羧和 Giese 反应：经典变换的实际应用

  摘要：

  已经重新研究了有机合成中两个具有根本重要性和最重要实用性的反应，即巴顿脱羧反应和吉斯自由基共轭加成反应。人们发现基于N-羟基邻苯二甲酰亚胺 (NHPI) 的氧化还原活性酯是简单、热、Ni 催化自由基形成以及随后用氢原子源 (PhSiH 3 ) 或缺电子烯烃捕获的方便起始材料。这些反应具有操作简单、试剂便宜和范围扩大的特点，肽化学领域的例子证明了这一点。

  DOI：

  10.1002/anie.201609662
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸甲酯 在 lithium hydroxide monohydrate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 1-Boc-4-甲基-4-哌啶甲酸
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS
  [FR] COMPOSÉS ET MÉTHODES

  摘要：

  本发明涉及新型视黄醛酸相关孤儿受体γ（RORγ）调节剂及其在治疗由RORγ介导的疾病中的应用。

  公开号：

  WO2013019621A1

文献信息

• [EN] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS<br/>[FR] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR H3 DE L'HISTAMINE
  申请人：SCHERING CORP

  公开号：WO2003103669A1

  公开（公告）日：2003-12-18

  Disclosed are histamine H3 antagonists of the formula (I) wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula (I) in combination with a H1 receptor antagonist.

  揭示了公式（I）中的组胺H3拮抗剂，其中R1是苯并咪唑酮衍生物，M1和M2是可选择地取代的碳或氮，R2包括可选择地取代的芳基或杂环基，其余变量如规范中所定义。还揭示了包括公式（I）化合物的药物组合物。还揭示了使用公式（I）化合物治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）的方法。还揭示了使用公式（I）化合物与H1受体拮抗剂结合治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）。
• NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES
  申请人：Ackermann Jean

  公开号：US20110065707A1

  公开（公告）日：2011-03-17

  The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the significance given herein.

  本发明涉及式(I)的化合物以及其药学上可接受的盐，其中A1、A2、R1、R2、R3、R4、R5和R6具有本文中给出的含义。
• [EN] HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE HSL UTILES DANS LE TRAITEMENT DU DIABÈTE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011029808A1

  公开（公告）日：2011-03-17

  Compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1,R2 R3,R4 R5 and R6 have the significance given in claim 1. Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of illnesses, especially in the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity.

  化合物的化学式（I），以及其药学上可接受的盐可以用作药物组合物的形式，其中A1，A2，R1，R2，R3，R4，R5和R6具有权利要求1中给定的含义。本发明的目的是化学式（I）的化合物及其上述的盐和酯，以及它们作为治疗活性物质的用途，制造所述化合物的方法，中间体，含有所述化合物的药物组合物，含有所述化合物、其药学上可接受的盐或酯的药物，所述化合物、盐或酯的用途用于治疗或预防疾病，特别是用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症，以及所述化合物、盐或酯的用途用于生产用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症的药物。
• Organocatalytic decarboxylative alkylation of <i>N</i>-hydroxy-phthalimide esters enabled by pyridine-boryl radicals
  作者：Liuzhou Gao、Guoqiang Wang、Jia Cao、Dandan Yuan、Cheng Xu、Xuewen Guo、Shuhua Li

  DOI：10.1039/c8cc06152a

  日期：——

  The decarboxylative alkylation of N-hydroxyphthalimide (NHPI) based reactive esters with olefins has been achieved via an organocatalytic strategy. Control experiments and density functional theory calculations suggest that these reactions involve a boryl-radical mediated decarboxylation pathway, which is different from the single electron transfer involved in decarboxylative alkylation reactions reported

  N-羟基邻苯二甲酰亚胺（NHPI）基反应性酯与烯烃的脱羧烷基化已通过有机催化策略实现。对照实验和密度泛函理论计算表明，这些反应涉及硼基自由基介导的脱羧途径，该途径不同于先前报道的脱羧烷基化反应中涉及的单电子转移。这种无金属的脱羧烷基化反应具有良好的功能相容性，并且通过烷基和芳基羧酸衍生物的转化说明了广泛的底物范围。
• Organophotoredox-Catalyzed Formation of Alkyl–Aryl and −Alkyl C–S/Se Bonds from Coupling of Redox-Active Esters with Thio/Selenosulfonates
  作者：Yue Dong、Peng Ji、Yueteng Zhang、Changqing Wang、Xiang Meng、Wei Wang

  DOI：10.1021/acs.orglett.0c03624

  日期：2020.12.18

  A mild organophotoredox synthetic protocol for forming a Csp3–S/Se bond by reacting widespread redox-active esters with thio/selenosulfonates has been developed. The power of the synthetic manifold is fueled by an unprecedented broad substrate scope and wide functional group tolerance.

  已经开发出一种温和的有机光氧化还原合成方案，通过使广泛的氧化还原活性酯与硫代/硒磺酸盐反应形成 C sp 3 –S/Se 键。前所未有的广泛底物范围和广泛的官能团耐受性推动了合成歧管的力量。